Novartis $NVS just delivered another quarter of strong product growth. Revenue and core EPS both topped expectations, driven by double-digit growth across key medicines including Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix. The company maintained its full-year outlook.
View on X ↗